Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPC2 CAR T in Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
NCT05650749Phase 1Enrolling by invitation
- Start
- May 2023
- Primary completion
- Jan 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of GPC2-directed CAR T-cell therapy in neuroblastoma and retinoblastoma (Rb) (2 arms). Primary endpoints: Maximum Tolerated Dose at 5 years and Adverse Events at 5 years. Started May 2023; status: enrolling by invitation.
02
Drugs
GPC2-directed CAR T-cell therapy
03
Conditions
neuroblastomaretinoblastoma (Rb)
Beyond the preview
Go deeper on NCT05650749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05650749.